drugset / Trial / NCT03329846
An Investigational Immuno-therapy Study of BMS-986205 Combined With Nivolumab, Compared to Nivolumab by Itself, in Patients With Advanced Melanoma
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to see if BMS-986205 combined with nivolumab, compared to nivolumab by itself, is more effective in treating Melanoma that has spread or is unable to be removed by surgery, and has not previously been treated
Timeline
- Start
- 2017-11-30
- Primary completion
- 2020-07-02
- Completion
- 2020-07-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LINRODOSTAT | Small molecule | — | — |
| Subject | Nivolumab | Monoclonal antibody | — | — |